Jeremy B. Hayden, Chief Legal Officer at Sight Sciences, Inc. (NASDAQ:SGHT), executed a transaction involving the sale of 12,733 shares of the company's common stock on July 6, 2026. The transaction was structured to cover tax liabilities associated with the vesting of restricted stock units. The shares were sold at a weighted average price of $5.508 per share, with individual transaction prices ranging from $5.37 to $5.62. The total value of the sale amounted to $70,133.
Following this transaction, Mr. Hayden directly holds 357,037 shares of Sight Sciences common stock. This total includes 100,015 shares of common stock and 257,022 shares that are expected to be acquired upon the vesting and settlement of unvested restricted stock units. The stock currently trades at $5.48, close to the insider's sale price. According to InvestingPro analysis, SGHT appears overvalued at current levels, placing it among stocks on the Most Overvalued list.
In other recent news, Sight Sciences reported its first-quarter 2026 earnings, showcasing a mixed set of results. The company achieved a revenue of $19.7 million, surpassing expectations by 6.2%. However, its earnings per share (EPS) came in at -$0.24, missing the forecast by 41.18%. These financial results indicate a stronger-than-expected revenue performance but a disappointing EPS outcome. There were no significant stock movements following the announcement. This revenue achievement and EPS shortfall reflect the company's current financial standing.
Investors and analysts will likely keep a close watch on Sight Sciences' future earnings reports for further insights. The combination of insider selling activity and mixed financial results highlights the ongoing evaluation of the company's valuation and operational performance within the medical device sector.